Drugs / hAd5-S-Fusion+N-ETSD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06022224 | Dec 2020 → Jun 2022 | COVID-19 | ImmunityBio, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hAd5-S-Fusion+N-ETSD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06022224 ↗ |
| Modality | Vaccine | “A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine” NCT06022224 ↗ |
| Route | Subcutaneous | “Prime (SC, Day 1) + Boost (SC, Day 22)” NCT06022224 ↗ |